DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent

What happened

DataMEDS AI terminated its October 19, 2026 letter of intent with Datavault AI, REBOOT Health AI, EOS, Scilex and HealthBridge Advisors for a possible intellectual-property license or acquisition in exchange for DataMEDS common stock, citing market conditions. It says no fees or obligations are due and no shares will be issued under the letter. Its separate REBOOT and Datavault AI agreements remain in force.

Confirmed

Global impact / market context

The termination removes a planned share-based route for DataMEDS to obtain additional intellectual property, so the listed counterparties will not receive shares under this letter. That avoids related share issuance but also leaves the proposed IP arrangement unrealized; the two separately identified agreements continue.

Analyst inference

The announcement links the decision to market conditions but gives no details about what changed, the value of the proposed IP, or the expected financial effect. Investors therefore have limited information to assess whether ending the deal reduces costs or constrains DataMEDS’s plans.

Analyst inference

What to watch

1. Check future company announcements for any replacement IP license or acquisition plan, including its terms and whether DataMEDS would issue shares or pay cash. Analyst inference
2. Watch for updates on the separate REBOOT license for managing GLP-1 users and the Datavault AI PharmacyChain agreement, both stated to remain in force. Confirmed
3. Look for financial disclosures that clarify whether the terminated letter involved costs, expected revenue, or operational plans beyond the stated absence of fees and obligations. Analyst inference

Evidence

• accessnewswire.com